 |  |  |
|---|---|---|
 |  |  |
DAVID A. DREW, PHD
LABORATORY
Welcome! Learn more about the research being performed by Dr. David A. Drew and the MGH Clinical & Translational Epidemiology Unit Biobank
RESEARCH
Specific Areas of Interest
Our lab focuses on translating epidemiological and clinical observations into biological mechanisms for disease that may be leveraged for precision medicine biomarker development.
CTEU BIOBANK
It is the mission of the CTEU Biobank to assist researchers within the CTEU performing clinical trials to provide clinical research coordination, wide-ranging biorepository support, and downstream biological specimen handling and preparation to rapidly advance proposed analyses.
COVID SYMPTOM TRACKER
Through a unique industry-academia collaboration, we have launched the COVID Symptom Tracker smartphone app in the US, UK and Sweden to better understand the global COVID-19 pandemic. This real-time epidemiology tool allows us to identify hotspots according to symptom reporting by users.
ASPIRIN CHEMOPREVENTION
We have developed several translational approaches and a robust biobank of patient-derived biopsecimens from individuals at risk for colorectal cancer as a part of the ASPIRED randomized, placebo-controlled trial.
THE GUT MICROBIOME
Our lab aims to understand microbial determinants of human health using whole-shotgun meta'omics (metagenomes, metatranscriptomes, and metabolomes) derived from human fecal samples. Specific projects aim to understand microbially-mediated mechanisms of chemoprevention or immunotherapy-related adverse events.